Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)
Vertex Pharmaceuticals' (VRTX) quarterly Total Non-Current Liabilities came in at $5.9 billion in Q1 2026, up 8.0% year-on-year from $5.4 billion in Q1 2025, and up 2.79% quarter-over-quarter from $5.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $5.9 billion for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 8.0% year-over-year to $5.9 billion in Q1 2026; TTM through Mar 2026 was $5.9 billion, a 8.0% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 11.72% from the prior year.
- Total Non-Current Liabilities grew to $5.9 billion in Q1 2026 per VRTX's latest filing, from $5.7 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6.3 billion in Q3 2025 and bottomed at $3.2 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $4.5 billion (2024), against an average of $4.7 billion.
- Across the five-year window, Total Non-Current Liabilities gained 6.71% in 2022 and soared 30.66% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $3.6 billion in 2022, then climbed by 20.26% to $4.3 billion in 2023, then climbed by 19.59% to $5.1 billion in 2024, then advanced by 11.72% to $5.7 billion in 2025, then climbed by 2.79% to $5.9 billion in 2026.
- Per Business Quant, the three latest VRTX Total Non-Current Liabilities figures stand at $5.9 billion (Q1 2026), $5.7 billion (Q4 2025), and $6.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.87 Bn |
| Dec 31, 2025 | 5.71 Bn |
| Sep 30, 2025 | 6.31 Bn |
| Jun 30, 2025 | 5.67 Bn |
| Mar 31, 2025 | 5.43 Bn |
| Dec 31, 2024 | 5.11 Bn |
| Sep 30, 2024 | 5.68 Bn |
| Jun 30, 2024 | 4.48 Bn |
| Mar 31, 2024 | 4.52 Bn |
| Dec 31, 2023 | 4.27 Bn |
| Sep 30, 2023 | 4.34 Bn |
| Jun 30, 2023 | 4.12 Bn |
| Mar 31, 2023 | 3.82 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.56 Bn |
| Jun 30, 2022 | 3.52 Bn |
| Mar 31, 2022 | 3.23 Bn |
| Dec 31, 2021 | 3.03 Bn |
| Sep 30, 2021 | 2.98 Bn |
| Jun 30, 2021 | 2.92 Bn |